Mr. Nassif joined Pharvaris in 2024, bringing more than 30 years of life sciences industry experience in executive financial management roles in development-stage, commercial-stage, public and private companies.
Mr. Nassif served as Chief Executive Officer, Chief Financial Officer, and Board Member of at Sio Gene Therapies, where he was responsible for all finance, accounting, tax, treasury, legal, and SEC compliance and reporting activities until February 2022, when he undertook the liquidation and dissolution of the company. Prior to joining Sio, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in its acquisition by United Therapeutics in August 2018. From 2011 to 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen. Previously, he was Executive Vice President and Chief Financial Officer of Zogenix and held several key roles at Amphastar Pharmaceuticals and RealAge Inc. Earlier in his career, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc.
He holds a BS in finance and management information systems with honors from the University of Virginia and a JD from the University of Virginia School of Law.
What is David W. Nassif's net worth?
The estimated net worth of David W. Nassif is at least $3.60 million as of May 21st, 2026. Nassif owns 120,300 shares of Pharvaris stock worth more than $3,595,767 as of June 3rd. This net worth evaluation does not reflect any other investments that Nassif may own. Learn More about David W. Nassif's net worth.
How do I contact David W. Nassif?
Has David W. Nassif been buying or selling shares of Pharvaris?
Over the course of the past ninety days, David W. Nassif has sold $303,100.00 in shares of Pharvaris stock. Most recently, David W. Nassif sold 10,000 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $30.31, for a transaction totalling $303,100.00. Following the completion of the sale, the chief financial officer now directly owns 120,300 shares of the company's stock, valued at $3,646,293. Learn More on David W. Nassif's trading history.
Who are Pharvaris' active insiders?
Are insiders buying or selling shares of Pharvaris?
In the last twelve months, insiders at the sold shares 24 times. They sold a total of 209,948 shares worth more than $6,268,140.96. The most recent insider tranaction occured on May, 22nd when insider Anna Nijdam sold 5,501 shares worth more than $169,100.74.
Learn More about insider trades at Pharvaris. Information on this page was last updated on 5/22/2026.
